Chinese contract research organization GemPharmatech has expanded its presence in the United States with a new facility in San Diego, announced on April 17. The facility is designed for laboratories and housing genetically engineered mouse models, aimed at enhancing their capabilities in offering
With over 300 million people globally suffering from chronic hepatitis B, the disease presents a monumental challenge in the realm of public health. Traditional treatments have mainly focused on suppressing the virus rather than providing a cure, demanding lifelong therapy for many patients.
Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, has achieved a groundbreaking milestone. Their investigational product, ALLO-329, has received three Fast Track Designations (FTDs) from the FDA, marking a significant advancement in the treatment of
Metastatic breast cancer remains one of the most challenging forms of cancer to treat, with only about one-third of patients surviving beyond five years post-diagnosis. Traditional treatments such as chemotherapy, radiation, and surgery have shown limited effectiveness, often accompanied by
Verve Therapeutics has announced a significant advancement in genetic medicine as their investigational drug VERVE-102 receives Fast Track designation from the U.S. Food and Drug Administration (FDA). This approval marks a crucial step in the development of treatments for hyperlipidemia and
Recce Pharmaceuticals, a Sydney-based biotechnology company, has successfully raised A$15.8 million to advance its groundbreaking anti-infective drugs into Phase 3 trials. This funding was obtained through a combination of private placement and an entitlement offer. Recce's synthetic